tiprankstipranks
Advertisement
Advertisement

GALT Stock Latest News

Galectin Therapeutics presents belapectin data at EASL 2026
The FlyGalectin Therapeutics presents belapectin data at EASL 2026
3d ago
GALT
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
PremiumThe Fly
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
19d ago
GALT
Galectin Therapeutics files $200M mixed securities shelf
PremiumThe Fly
Galectin Therapeutics files $200M mixed securities shelf
2M ago
GALT
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
2M ago
GALT
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
PremiumCompany Announcements
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
2M ago
8K
GALT
Galectin Therapeutics appoints Henry Brem to board of directors
PremiumThe FlyGalectin Therapeutics appoints Henry Brem to board of directors
2M ago
GALT
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
Premium
Ratings
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
3M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Premium
Company Announcements
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
3M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
PremiumCompany Announcements
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
3M ago
GALT
Galectin Therapeutics Approves Retention Bonuses for Key Executives
PremiumCompany Announcements
Galectin Therapeutics Approves Retention Bonuses for Key Executives
4M ago
8K
GALT
Galectin Therapeutics announces board resignation of Marc Rubin
PremiumCompany Announcements
Galectin Therapeutics announces board resignation of Marc Rubin
5M ago
8K
GALT
Galectin Advances Belapectin Program, Secures New Insider Financing
PremiumCompany Announcements
Galectin Advances Belapectin Program, Secures New Insider Financing
5M ago
8K
GALT
Galectin Therapeutics provides regulatory update following FDA written response
PremiumThe FlyGalectin Therapeutics provides regulatory update following FDA written response
5M ago
GALT
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
Premium
The Fly
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
5M ago
GALT
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
6M ago
8K
GALT
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
PremiumCompany Announcements
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
6M ago
8K
GALT
Galectin Therapeutics Reports Q3 2025 Financials
PremiumCompany Announcements
Galectin Therapeutics Reports Q3 2025 Financials
7M ago
GALT
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
PremiumRatings
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
7M ago
GALT
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
PremiumThe Fly
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
7M ago
GALT
Galectin Therapeutics presents NAVIGATE trial results at AASLD
PremiumThe FlyGalectin Therapeutics presents NAVIGATE trial results at AASLD
7M ago
GALT
Galectin Therapeutics Presents Promising NAVIGATE Trial Results
Premium
Company Announcements
Galectin Therapeutics Presents Promising NAVIGATE Trial Results
7M ago
8K
GALT
Galectin Therapeutics Highlights Promising Belapectin Results
Premium
Company Announcements
Galectin Therapeutics Highlights Promising Belapectin Results
9M ago
8K
GALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >